Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Supernus to Present at Three November Healthcare Conferences


Posted on: 07 Nov 16

ROCKVILLE, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the following three conferences:

Stifel 2016 Healthcare Conference
Date: Tuesday, November 15, 2016
Time: 10:15 a.m. EST
Place: Lotte New York Palace Hotel, New York

Jefferies London Healthcare Conference
Date: Thursday, November 17, 2016
Time: 3:20 p.m. GMT (10:20 p.m. EST)
Place: Waldorf Hilton, London, U.K.

Piper Jaffray 28th Annual Healthcare Conference
Date: Tuesday, November 29, 2016
Time: 9:00 p.m. EST
Place: Lotte New York Palace Hotel, New York

Investors interested in arranging a meeting with the Company's management during these conferences should contact the conference coordinator.

A live webcast of the presentations can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days on the Company's website after each conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in patients with ADHD and SPN-812 for the treatment of ADHD.

GlobeNewswire
globenewswire.com

Last updated on: 08/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.